{"id":"NCT02054702","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia","officialTitle":"Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2014-06","completion":"2014-07","firstPosted":"2014-02-04","resultsPosted":"2015-12-01","lastUpdate":"2015-12-30"},"enrollment":97,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]},{"type":"DRUG","name":"Aripiprazole","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"},{"label":"Aripiprazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia","primaryOutcome":{"measure":"Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Baseline to Week 6","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-22.9,"sd":1.7},{"arm":"Aripiprazole","deltaMin":-19.4,"sd":2.4}],"pValues":[{"comp":"OG000","p":"<0.0001"},{"comp":"OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":64},"commonTop":["Akathisia","Weight increased","Headache","Dyspepsia","Dry mouth"]}}